Pfizer
Search results
We’re on the road with a new approach to clinical trials—one that expands access to cutting-edge medicines and treatments. Lilly is a medicine company turning science into healing to make life better for people around the world.
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Eli Lilly and Company works tirelessly to develop and deliver trusted medicines that meet real needs. These include Trulicity, Humalog, Alimta, Forteo, Taltz, Humulin, Basaglar, Jardiance, Cyramza, REYVOW, Verzenio, Emgality and more.
We’re a medicine company turning science into healing to make life better for people around the world. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges.
Jun 21, 2024 · The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Find your place at Lilly with Lilly Careers. For more than a century, we have united caring with discovery to make life better, join us today.
Jun 10, 2024 · June 10, 2024 at 4:00 PM EDT. Goldman Sachs 45th Annual Global Healthcare Conference. Speaker: Patrik Jonsson, Executive Vice President, President of Lilly Diabetes and Obesity and Lilly USA. Listen to Webcast.
Find the latest Eli Lilly and Company (LLY) stock quote, history, news and other vital information to help you with your stock trading and investing.
Nov 8, 2023 · INDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone ...
2 days ago · The Food and Drug Administration on Tuesday approved Eli Lilly 's Alzheimer's drug donanemab, expanding the limited treatment options for the mind-wasting disease in the U.S. The agency approved ...
